Tesaro: Is The Selloff Overdone?

The initial panic that surrounded shares of Tesaro (TSRO) this morning appears to have eased back quite a bit. Tesaro is one of three leaders in the market for so-called PARP inhibitors, a new class of cancer drug. Earlier today, rival Clovis Oncology (CLVS) released data for its drug Rubraca that fueled worries about Tesaro’s […]